PDE5A and pulmonary arterial hypertension: Currently, the drug sildenafil 20 mg, which belongs to the class of PDE5 inhibitors, is incorporated into the universal healthcare system for pulmonary arterial hypertension, and there has also been evidence of increased access to sildenafil 25 mg and 50 mg for the treatment of systemic sclerosis.